Germ cell tumors of the ovary: An update

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 3, 2014, Pages 351-362

  Nogales, Francisco F ^a   Dulcey, Isabel ^a   Preda, Ovidiu ^b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Department of Research and Development Master Diagnostica ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; FEMALE; HUMAN; METABOLISM; NEOPLASM; OVARY; OVARY TUMOR; PATHOLOGY;

FEMALE; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84895539734     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0547-RA     Document Type: Article

References (90)

1. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34(5): 427-441.
2. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20): 2938-2943.
3. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18(suppl 2):S61-S79.
4. Lee ST, Choi MH, Lee EJ, et al. Establishment of autologous embryonic stem cells derived from preantral follicle culture and oocyte parthenogenesis. Fertil Steril. 2008;90(5): 1910-1920.
5. Stevens LC. Teratocarcinogenesis and spontaneous parthenogenesis in mice. Results Probl Cell Differ. 1980;11: 265-274.
6. Sheikine Y, Genega E, Melamed J, Lee P, Reuter VE, Ye H. Molecular genetics of testicular germ cell tumors. Am J Cancer Res. 2012;2(2): 153-167.
7. Cossu-Rocca P, Zhang S, Roth LM, et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Mod Pathol. 2006;19(4): 611-615.
8. Oosterhuis JW, Stoop H, Honecker F, Looijenga LH. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives [discussion in Int J Androl. 2007;30(4): 263-264]. Int J Androl. 2007;30(4): 256-263.
9. Poulos C, Cheng L, Zhang S, Gersell DJ, Ulbright TM. Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 2006;19(6): 766-771.
10. Cooper C, Cooper M, Carter J, Russell P. Gonadoblastoma progressing to dysgerminoma in a 55-year-old woman with normal karyotype. Pathology. 2007; 39(2): 284-285.
11. Hertel JD, Huettner PC, Dehner LP, Pfeifer JD. The chromosome Y-linked testis-specific protein locus TSPY1 is characteristically present in gonadoblastoma. Hum Pathol. 2010;41(11): 1544-1549.
12. Meyer R. Ovarialtumoren und Geschlechtlichkeit. Ein Beitrag zur funktionellen Betrachtung der Geschwülste: I. "Disgerminome" beider Geschlechter bei St örung in der Entwicklung der Keimdrüsen, II. Granulosazelltumoren mit "Verweiblichung," III. Arrhenoblastome mit "Vermännlichung." Klin Wochenschr. 1930;9: 2237-2240.
13. Thomas J, Adegboyega P, Iloabachie K, Mooring JW, Lian T. Sinonasal teratocarcinosarcoma with yolk sac elements: a neoplasm of somatic or germ cell origin? Ann Diagn Pathol. 2011;15(2): 135-139.
14. Garcia-Galvis OF, Stolnicu S, Munoz E, Aneiros-Fernandez J, Alaggio R, Nogales FF. Adult extrarenal Wilms tumor of the uterus with teratoid features. Hum Pathol. 2009;40(3): 418-424.
15. Garcia-Galvis OF, Cabrera-Ozoria C, Fernandez JA, Stolnicu S, Nogales FF. Malignant Mullerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol. 2008;27(4): 515-520.
16. Nogales FF, Preda O, Nicolae A. Yolk sac tumours revisited: a review of their many faces and names. Histopathology. 2012;60(7): 1023-1033.
17. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 1964;24: 1544-1551.
18. Tapia N, Arauzo-Bravo MJ, Ko K, Scholer HR. Concise review: challenging the pluripotency of human testis-derived ESC-like cells. Stem Cells. 2011;29(8): 1165-1169.
19. Wang Z, Oron E, Nelson B, Razis S, Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell. 2012;10(4): 440-454.
20. Hadrup SR, Braendstrup O, Jacobsen GK, et al. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer. 2006;119(4): 831-838.
21. Nogales FF. The pathology of germ cell tumours. In: Fox H, Wells M, eds. Obstetrical and Gynaecological Pathology. Vol 1. London, England: Churchill Livingstone; 2003: 773-777.
22. Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med. 2012;136(4): 435-446.
23. Kao CS, Idrees MT, Young RH, Ulbright TM. Solid pattern yolk sac tumor: a morphologic and immunohistochemical study of 52 cases. Am J Surg Pathol. 2012;36(3): 360-367.
24. Iczkowski KA, Butler SL, Shanks JH, et al. Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol. 2008;39(2): 275-281.
25. Cheng L, Roth LM, Zhang S, et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer. 2011;117(10): 2096-2103.
26. Sever M, Jones TD, Roth LM, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005;18(11): 1411-1416.
27. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151(4): 1141-1152.
28. Ordoñez NG. Immunohistochemical endothelial markers: a review. Adv Anat Pathol. 2012;19(5): 281-295.
29. Chang MC, Vargas SO, Hornick JL, Hirsch MS, Crum CP, Nucci MR. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int J Gynecol Pathol. 2009;28(4): 347-355.
30. Idrees M, Saxena R, Cheng L, Ulbright TM, Badve S. Podoplanin, a novel marker for seminoma: a comparison study evaluating immunohistochemical expression of podoplanin and OCT3/4. Ann Diagn Pathol. 2010;14(5): 331-336.
31. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol. 2007; 20(3): 320-325.
32. Boheler KR. Stem cell pluripotency: a cellular trait that depends on transcription factors, chromatin state and a checkpoint deficient cell cycle. J Cell Physiol. 2009;221(1): 10-17.
33. Cantz T, Key G, Bleidissel M, et al. Absence of OCT4 expression in somatic tumor cell lines. Stem Cells. 2008;26(3): 692-697.
34. Chassot AA, Gregoire EP, Lavery R, et al. RSPO1/beta-catenin signaling pathway regulates oogonia differentiation and entry into meiosis in the mouse fetal ovary. PLoS One. 2011;6(10):e25641.
35. Rijlaarsdam MA, van Herk HA, Gillis AJ, et al. Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours. Br J Cancer. 2011; 105(6): 854-863.
36. Abiko K, Mandai M, Hamanishi J, et al. Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. Am J Surg Pathol. 2010;34(12): 1842-1848.
37. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007;31(6): 836-845.
38. Eildermann K, Aeckerle N, Debowski K, et al. Developmental expression of the pluripotency factor sal-like protein 4 in the monkey, human and mouse testis: restriction to premeiotic germ cells. Cells Tissues Organs. 2012;196(3): 206-220.
39. Trinh DT, Shibata K, Hirosawa T, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. J Obstet Gynaecol Res. 2012;38(5): 841-848.
40. Ikeda H, Sato Y, Yoneda N, et al. alpha-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Hum Pathol. 2012;43(11): 1955-1963.
41. Lu J, Ma Y, Kong N, et al. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia. 2011;25(7): 1211-1213.
42. Battifora H, Sheibani K, Tubbs RR, Kopinski MI, Sun TT. Antikeratin antibodies in tumor diagnosis: distinction between seminoma and embryonal carcinoma. Cancer. 1984;54(5): 843-848.
43. Parkash V, Carcangiu ML. Transformation of ovarian dysgerminoma to yolk sac tumor: evidence for a histogenetic continuum. Mod Pathol. 1995;8(8): 881-887.
44. Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol. 1993;17(1): 1-13.
45. Nogales-Fernandez F, Silverberg SG, Bloustein PA, Martinez-Hernandez A, Pierce GB. Yolk sac carcinoma (endodermal sinus tumor): ultrastructure and histogenesis of gonadal and extragonadal tumors in comparison with normal human yolk sac. Cancer. 1977;39(4): 1462-1474.
46. Teilum G, Albrechtsen R, Norgaard-Pedersen B. The histogeneticembryologic basis for reappearance of alpha-fetoprotein in endodermal sinus tumors (yolk sac tumors) and teratomas. Acta Pathol Microbiol Scand A. 1975; 83(1): 80-86.
47. Nogales FF Jr, Matilla A, Nogales-Ortiz F, Galera-Davidson HL. Yolk sac tumors with pure and mixed polyvesicular vitelline patterns. Hum Pathol. 1978; 9(5): 553-566.
48. Prat J, Bhan AK, Dickersin GR, Robboy SJ, Scully RE. Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases. Cancer. 1982;50(11): 2355-2368.
49. Cohen MB, Friend DS, Molnar JJ, Talerman A. Gonadal endodermal sinus (yolk sac) tumor with pure intestinal differentiation: a new histologic type. Pathol Res Pract. 1987;182(5): 609-616.
50. Nogales FF, Buritica C, Regauer S, Gonzalez T. Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors. Am J Surg Pathol. 2005;29(9): 1247-1251.
51. Nogales FF, Bergeron C, Carvia RE, Alvaro T, Fulwood HR. Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm: analysis of six cases. Am J Surg Pathol. 1996;20(9): 1056-1066.
52. Nogales FF, Dulcey I. The secondary human yolk sac has an immunophenotype indicative of both hepatic and intestinal differentiation [published online ahead of print October 22, 2012]. Int J Dev Biol. doi:10.1387/ijdb.120080fn.
53. Damjanov I, Amenta PS, Zarghami F. Transformation of an AFP-positive yolk sac carcinoma into an AFP-negative neoplasm: evidence for in vivo cloning of the human parietal yolk sac carcinoma. Cancer. 1984;53(9): 1902-1907.
54. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16(2): 125-129.
55. Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008; 130(2): 224-230.
56. Preda O, Nicolae A, Aneiros-Fernandez J, Borda A, Nogales FF. Glypican 3 is a sensitive, but not a specific, marker for the diagnosis of yolk sac tumours [author reply in Histopathology. 2011;58(2): 314-315]. Histopathology. 2011; 58(2): 312-314.
57. Michael H, Ulbright TM, Brodhecker CA. The pluripotential nature of the mesenchyme-like component of yolk sac tumor. Arch Pathol Lab Med. 1989; 113(10): 1115-1119.
58. Pitman MB, Triratanachat S, Young RH, Oliva E. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma. Int J Gynecol Pathol. 2004;23(1): 58-64.
59. Bing Z, Pasha T, Tomaszewski JE, Zhang P. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17(5): 373-377.
60. Xue D, Peng Y, Wang F, Allan RW, Cao D. RNA-binding protein LIN28 is a sensitive marker of ovarian primitive germ cell tumours. Histopathology. 2011; 59(3): 452-459.
61. Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNAbinding proteins (IMPs) in gonads and testicular cancer. Reproduction. 2005; 130(2): 203-212.
62. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30(3): 277-299.
63. Berney DM. Update on testis tumours. Pathology. 2012;44(5): 419-426.
64. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133(3): 446-450.
65. Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected smallcell population. Int J Cancer. 1982;30(4): 445-459.
66. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647: 174-185.
67. Noisa P, Ramasamy TS, Lamont FR, et al. Identification and characterisation of the early differentiating cells in neural differentiation of human embryonic stem cells. PLoS One. 2012;7(5):e37129.
68. McCluggage WG. Value of inhibin staining in gynecological pathology. Int J Gynecol Pathol. 2001;20(1): 79-85.
69. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132(3): 402-423.
70. Wesselschmidt RL. The teratoma assay: an in vivo assessment of pluripotency. Methods Mol Biol. 2011;767: 231-241.
71. Stolnicu S, Furtado A, Sanches A, et al. Ovarian ependymomas of extraaxial type or central immunophenotypes. Hum Pathol. 2011;42(3): 403-408.
72. Rutgers JL, Young RH, Scully RE. Ovarian yolk sac tumor arising from an endometrioid carcinoma. Hum Pathol. 1987;18(12): 1296-1299.
73. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010;28(9): 1568-1570.
74. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5): 1075-1085.
75. Gershenson DM. Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecol Oncol. 2012;125(3): 515-517.
76. O'Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol. 1994;13(4): 283-289.
77. Nogales FF Jr, Favara BE, Major FJ, Silverberg SG. Immature teratoma of the ovary with a neural component ("solid" teratoma): a clinicopathologic study of 20 cases. Hum Pathol. 1976;7(6): 625-642.
78. Kleinman GM, Young RH, Scully RE. Primary neuroectodermal tumors of the ovary: a report of 25 cases. Am J Surg Pathol. 1993;17(8): 764-778.
79. Yanai-Inbar I, Scully RE. Relation of ovarian dermoid cysts and immature teratomas: an analysis of 350 cases of immature teratoma and 10 cases of dermoid cyst with microscopic foci of immature tissue. Int J Gynecol Pathol. 1987;6(3): 203-212.
80. Nogales FF, Aguilar D. Florid vascular proliferation in grade 0 glial implants from ovarian immature teratoma. Int J Gynecol Pathol. 2002;21(3): 305-307.
81. Dadmanesh F, Miller DM, Swenerton KD, Clement PB. Gliomatosis peritonei with malignant transformation. Mod Pathol. 1997;10(6): 597-601.
82. Ferguson AW, Katabuchi H, Ronnett BM, Cho KR. Glial implants in gliomatosis peritonei arise from normal tissue, not from the associated teratoma. Am J Pathol. 2001;159(1): 51-55.
83. Kwan MY, Kalle W, Lau GT, Chan JK. Is gliomatosis peritonei derived from the associated ovarian teratoma? Hum Pathol. 2004;35(6): 685-688.
84. Best DH, Butz GM, Moller K, Coleman WB, Thomas DB. Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumors. Int J Oncol. 2004;25(1): 17-25.
85. Perrone T, Steiner M, Dehner LP. Nodal gliomatosis and alpha-fetoprotein production: two unusual facets of grade I ovarian teratoma. Arch Pathol Lab Med. 1986;110(10): 975-977.
86. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007;31(6): 854-869.
87. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12): 1091-1098.
88. Dalmau J, Tuzun E,Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1): 25-36.
89. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4): 594-604.
90. Dulcey I, Cespedes MU, Ballesteros JL, et al. Necrotic mature ovarian teratoma associated with anti-N-methyl-D-aspartate receptor encephalitis. Pathol Res Pract. 2012;208(8): 497-500.